STOCK TITAN

Kazia Therapeutics files its FY2026 annual report

Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Kazia Therapeutics Limited (KZIA) filed its Annual Report for the fiscal year ended June 30, 2026, which includes audited consolidated financial statements. The report describes paxalisib as an investigational oral, brain-penetrant dual PI3K/mTOR inhibitor being developed for cancers including central nervous system, advanced breast and colorectal cancers. Kazia also describes NDL2 and MSETC as preclinical programs and EVT801 as a small molecule VEGFR-3 inhibitor being explored for potential partnering.

brain-penetrant technical
"investigational oral, brain-penetrant dual PI3K/mTOR inhibitor"
A brain-penetrant drug or molecule can cross the brain’s natural security gate (the blood–brain barrier) to reach and act on cells inside the brain. For investors, that matters because treatments that reach the brain can address disorders like Alzheimer’s, depression, or brain cancer—opening large markets—but they also carry higher technical risk, stricter safety testing and unique regulatory challenges compared with drugs that act elsewhere in the body.
dual PI3K/mTOR inhibitor medical
"brain-penetrant dual PI3K/mTOR inhibitor"
Fast Track designation regulatory
"received U.S. FDA Fast Track designation"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Orphan Drug designation regulatory
"Fast Track and Orphan Drug designations"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
nuclear PD-L1 protein degrader medical
"NDL2, a nuclear PD-L1 protein degrader"
SETDB1 inhibitor medical
"MSETC, a SETDB1 inhibitor"
A SETDB1 inhibitor is a compound that blocks the activity of the enzyme SETDB1, a histone methyltransferase that adds methyl groups to histone H3 at lysine 9 (H3K9). By reducing SETDB1’s methylation activity, these inhibitors can change how tightly DNA is packaged and thereby alter the on/off state of genes that the enzyme normally represses; they are typically experimental or investigational agents used to modify gene expression through this epigenetic mechanism.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KZIA’s fiscal 2026 annual report include?

It includes audited consolidated financial statements for the fiscal year ended June 30, 2026.

How can shareholders get Kazia’s fiscal 2026 annual report?

The report is available on Kazia’s website and the SEC’s website; shareholders may also request a hard copy free of charge.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2026

Commission File Number: 000-29962

 

 

Kazia Therapeutics Limited

(Exact Name of Registrant as Specified in Its Charter)

 

 

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

 

 
 


INFORMATION CONTAINED IN THIS FORM 6-K REPORT

Press Release

On November 19, 2026, Kazia Therapeutics Limited (the “Company”) issued a press release titled “Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026”. The Company is furnishing a copy of this press release with this Report on Form 6-K as Exhibit 99.1.

The information in this Report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

EXHIBIT INDEX

The following exhibits are furnished as part of this Form 6-K:

 

Exhibit   

Description

99.1    Press Release dated November 19, 2026.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Kazia Therapeutics Limited
By:  

/s/ John Friend

Name:   John Friend
Title:   Chief Executive Officer

Date: November 19, 2026

Exhibit 99.1

Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026

SYDNEY, Australia, November 19, 2026 - Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended June 30, 2026 with the U.S. Securities and Exchange Commission (“SEC”).

The Annual Report, which includes the Company’s audited consolidated financial statements for fiscal year 2026, is available on the Company’s website and on the SEC’s website at www.sec.gov. Shareholders may receive a hard copy of the Annual Report, including the Company’s audited consolidated financial statements, free of charge upon request.

Fiscal 2026 Financial Highlights

 

  •  

Cash, cash equivalents and short-term investments of approximately A$61.2 million as of 30 June 2026.

 

  •  

The Company believes that its working capital, together with the net proceeds of the August 2026 public offering and the Sovargen milestone payment received in September 2026, is sufficient to fund its planned operations for at least the next 12 months from the date of the Annual Report.

Recent Highlights

 

  •  

Encouraging initial Stage IV TNBC data: 100% clinical benefit rate and 83% objective response rate (one complete response, four partial responses) in six evaluable patients treated with paxalisib-based regimens, with no paxalisib-related serious adverse events. Median reductions of 83% in metastasis-associated CTC clusters and 51% in terminally exhausted CD8+ T cells.

 

  •  

Oversubscribed public offering of up to US$120 million: Approximately US$40 million in upfront gross proceeds, with up to approximately US$80 million in additional gross proceeds from milestone-linked warrants tied to the Stage IV TNBC data readout (expected 2H 2027) and the HR+/HER2- data readout (expected 1H 2028).

 

  •  

Pipeline expanded into additional indications: Advancing a three-arm HR+/HER2- breast cancer expansion of the ongoing trial and a planned five-arm Phase 2 study in MSS/pMMR colorectal cancer, with CRC enrollment expected to commence in Q1 2027.


  •  

Clinical advancement across additional paxalisib programs: First patients dosed in two additional paxalisib trials – PNOC035 Arm A (paxalisib plus gemcitabine in recurrent or progressive pediatric AT/RT) and partner Sovargen’s Phase 1b/2a trial in rare mTORopathy-related epilepsies, the latter triggering a US$2 million milestone payment to Kazia.

 

  •  

Expanded intellectual property portfolio supporting paxalisib’s clinical development: Filed three provisional patent applications covering a perioperative treatment strategy in high-risk TNBC, resensitization of CDK4/6 inhibitor-resistant HR+/HER2- breast cancer, and therapeutic applications in MSS/pMMR colorectal cancer. The perioperative TNBC filing was supported by preclinical findings demonstrating a 95% reduction in residual disease and local recurrence (p<0.0001) following neoadjuvant chemo-immunotherapy and surgery.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance. Kazia’s lead asset, paxalisib, is an investigational oral, brain-penetrant dual PI3K/mTOR inhibitor being developed across multiple forms of cancer, including cancers of the central nervous system, advanced breast cancer and colorectal cancer. Paxalisib has received U.S. FDA Fast Track and Orphan Drug designations for glioblastoma, Fast Track designation for PI3K-altered brain metastases with radiation and Rare Pediatric Disease and Orphan Drug designations for select pediatric brain tumors, including diffuse intrinsic pontine glioma and atypical teratoid/rhabdoid tumor.

Kazia is also advancing two potentially first-in-class preclinical programs: NDL2, a nuclear PD-L1 protein degrader designed to address mechanisms of immunotherapy resistance and metastatic progression, and MSETC, a SETDB1 inhibitor intended to restore immune signaling in tumors that have become resistant to immunotherapy, including checkpoint inhibitors. Additionally, Kazia’s portfolio includes EVT801, a small molecule VEGFR-3 inhibitor that the Company is exploring for potential partnering opportunities. For more information, visit www.kaziatx.com, as well as follow us on X and LinkedIn.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are generally identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “may,” “will,” “could,” “should,” “estimates,” “projects,” “potential,” “suggests,” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding: the sufficiency of the Company’s cash, cash equivalents and short-term investments to fund its planned operations; the timing, design, initiation, enrollment, completion and data readouts of the Company’s ongoing and planned clinical trials, including in Stage IV TNBC, HR+/HER2- breast cancer and MSS/pMMR colorectal cancer; the potential exercise of the Series A and Series B warrants issued in the August 2026 public offering and any related proceeds; the potential therapeutic benefits and development of paxalisib, NDL2, MSETC and EVT801; the Company’s intellectual property strategy and provisional patent applications; and the activities of the Company’s collaborators, including Sovargen.

These forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release and are subject to significant risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to: the preliminary nature of early-stage clinical data, which may change as more patient data become available; the risk that results of preclinical and translational studies may not be predictive of results in clinical trials in humans; risks associated with the research and development of therapeutic programs; the timing, conduct and enrollment of the Company’s clinical trials; whether any Series A or Series B warrants will be exercised; regulatory review and approval processes; the Company’s need to raise substantial additional capital and its ability to obtain sufficient funding to advance its programs; reliance on third-party collaborators, contract research organizations and trial sites; the Company’s ability to obtain, maintain and protect its intellectual property; competition; general economic and market conditions; and the Company’s ability to maintain compliance with Nasdaq listing requirements.

For a more complete discussion of risks and uncertainties, please refer to the Company’s filings with the SEC, including the “Risk Factors” section of the Company’s most recent Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.


Investor Relations Contact

Mike Moyer

Managing Director, LifeSci Advisors LLC

Tel: 617-308-4306

Filing Exhibits & Attachments

1 document

Keep reading